| 靶点: |
proteasome β1i (LMP2) subunit inhibitor |
| 体内研究: |
ML604440 (腹膜内注射;10 mg/kg;每天一次;7 天) 处理在体内抑制 LMP2,血小板计数没有显著变化。 |
| 参考文献: |
1. de Bruin G, et al. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57(14):6197-209 2. Basler M, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018 Dec;19(12). pii: e46512. 3. Sheng-Hong Du, et al. Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia. Front Immunol. 2021 Jan 20;11:603278. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.576 ml |
12.88 ml |
25.761 ml |
| 5 mM |
0.515 ml |
2.576 ml |
5.152 ml |
| 10 mM |
0.258 ml |
1.288 ml |
2.576 ml |
| 50 mM |
0.052 ml |
0.258 ml |
0.515 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |